Evidence map›Paper›PMID 42698355›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026

Sarsasapogenin Preserves Podocyte Integrity and Attenuates Renal Injury in Experimental IgA Nephropathy.

Meltem Kumaş, Dilek Canlar Akar, Mehmet Gül, Erkan Karadaş, Selen Kum Özşengezer, Kadri Kulualp, Orhan Yavuz, Osman Yilmaz

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Meltem KumaşDepartment of Histology and Embryology, Faculty of Veterinary Medicine, Dokuz Eylul University, Izmir, Turkey.ORCID https://orcid.org/0000-0001-6903-3212
Dilek Canlar AkarDepartment of Biochemistry, Faculty of Veterinary Medicine, Dokuz Eylul University, Izmir, Turkey.
Mehmet GülDepartment of Histology and Embryology, Faculty of Medicine, Inonu University, Malatya, Turkey.
Erkan KaradaşDepartment of Pathology, Faculty of Veterinary Medicine, Dokuz Eylul University, Izmir, Turkey.
Selen Kum ÖzşengezerDepartment of Basic Oncology, Institute of Oncology, Dokuz Eylul University, Izmir, Turkey.
Kadri KulualpDepartment of Surgery, Faculty of Veterinary Medicine, Dokuz Eylul University, Izmir, Turkey.
Orhan YavuzDepartment of Pathology, Faculty of Veterinary Medicine, Dokuz Eylul University, Izmir, Turkey.
Osman YilmazDepartment of Laboratory Animal Science, Institute of Health Science, Dokuz Eylul University, Izmir, Turkey.

Funding

Dokuz Eylül Üniversitesi (DEÜ) TSG-2023-3262
6 · The paper itself

Abstract

IgA nephropathy (IgAN) is a progressive glomerular disease marked by mesangial IgA deposition, inflammation, podocyte injury, and fibrogenesis. Although understanding of its pathophysiology has advanced, effective disease-modifying therapies are still limited. Sarsasapogenin (SAR), a natural steroidal sapogenin, demonstrates anti-inflammatory, antioxidant, and antifibrotic properties by modulating signaling pathways such as NF-κB and TGF-β. The present study investigated the renoprotective effects of SAR in an experimental model of IgAN. IgAN was induced in Sprague-Dawley rats using bovine serum albumin (BSA), carbon tetrachloride (CCl

Indexed as

Glomerulonephritis, IGAKidneyPodocytesSpirostansAnimalsDisease Models, AnimalFibrosisIntracellular Signaling Peptides and ProteinsMaleMembrane ProteinsProteinuriaRatsRats, Sprague-DawleySmad3 ProteinTransforming Growth Factor beta1Intracellular Signaling Peptides and ProteinsMembrane ProteinssarsasapogeninSmad3 ProteinSpirostansTransforming Growth Factor beta1experimental modelIgA nephropathypodocyte injuryrenal fibrosissarsasapogeninTGF‐β/SMAD signaling

Identifiers

PMID42698355
PMCPMC13545654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.